- Joined
- Oct 13, 2008
- Messages
- 4,465
- Reaction score
- 8,880
So it has become clear over the past few years that as a profession we were sold a bill of goods about atypical/SGAs and the idea that they were essentially benign compared to older meds. People still argue about whether and exactly how much the EPS risk differs, but it is pretty clear they are significantly more sedating, metabolism-deranging, and weight gain inducing.
So! I would like to get to grips better with the finer nuances of older agents, but it seems like most people who trained since the late 90's aren't super comfortable with these agents with a couple of exceptions. The clinical lore and detaila about how these things might be used has been lost. Do any of you all have recommendations of papers or books that might cover this sort of thing? I can find lots of comparisons of SGAs and SGAs v. haldol (or sometimes Trilafon/Prolixin) but not so much comparing the FGAs to each other. I can sort of take educated guesses from receptors profiles but this is obviously not isomorphic with likely clinical effects.
Any suggestions?
So! I would like to get to grips better with the finer nuances of older agents, but it seems like most people who trained since the late 90's aren't super comfortable with these agents with a couple of exceptions. The clinical lore and detaila about how these things might be used has been lost. Do any of you all have recommendations of papers or books that might cover this sort of thing? I can find lots of comparisons of SGAs and SGAs v. haldol (or sometimes Trilafon/Prolixin) but not so much comparing the FGAs to each other. I can sort of take educated guesses from receptors profiles but this is obviously not isomorphic with likely clinical effects.
Any suggestions?